ClinicalTrials.gg
RecruitingNCT07389083Updated Feb 5, 2026

The Efficacy and Safety of the Supraglottic Oxygenation Via Nasotracheal Intubation for Deep Sedation Fiberoptic Bronchoscopy

An interventional study of wire-reinforced tracheal tube in Hypoxia, Pulmonary Nodule and Pulmonary Infection, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Hypoxia with a site in China — 44 open to participants now, 45 under way, none of them phase 3. Hypoxia · China.

Planned enrollment
68th of 78
50 · median 240
Started
2025
with 21 others
No phase
63 of 97
31 open now
Primary completion
2026-02
later than 14 of 44 live
Registered
75th of 97
by date
Lead sponsor
3 of 97
First Affiliated Hospital of Zhejiang University

Among the 97 studies in Hypoxia with a site in China, this one is the 68th largest by planned enrollment of the 78 interventional ones that give a count, is one of 22 that started in 2025, is one of 63 with no phase, reaches primary completion later than 14 of the 44 other live ones, and was the 75th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

44 of the 97 studies in Hypoxia with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Hypoxia with a site in China, or all of them as a file.
02

Study summary

Bronchoscopy is now widely used for the diagnosis and treatment of various respiratory diseases. However, the procedure is highly stimulating and provokes a strong stress response; because the airway is shared, patients are prone to hypoxia. With the growing emphasis on comfortable care, demand for anesthesia during bronchoscopy has increased. Deep sedation is the most common approach, but when administered in the supine position it often causes the tongue base to fall back. Both nasopharyngeal and oropharyngeal airways can relieve this obstruction, yet neither connects seamlessly to an oxygen supply line, resulting in insufficient oxygen delivery.We therefore replaced the nasopharyngeal airway with a wired endotracheal tube (size 4.0 or 4.5) inserted via the nose. This thinner tube couples easily to an oxygen line or ventilator circuit, partially relieves airway obstruction, and allows ample supraglottic oxygenation. The present study was designed to evaluate the feasibility and safety of this modified oxygen-delivery method in patients undergoing deep sedation for bronchoscopy.

03

Conditions studied

  • Hypoxia
  • Pulmonary Nodule
  • Pulmonary Infection

Browse trials for

Keywords

  • fiberoptic bronchoscopy
  • Hypoxia
  • Deep sedation
  • supine position
  • tongue-base fallback
  • supraglottic oxygenation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing fiberoptic bronchoscopy under deep sedation.
  • Written obtained from the patient or their legal representative.
  • Clear understanding of, and voluntary participation in, the study, with informed-consent form signed by the patient or their legal representative.

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • > 30 kg/m²
  • Previous history of abnormal recovery from anesthesia/surgery
  • History of recurrent epistaxis, nasal bone fracture, nasal polyps, or sinus surgery
  • Chronic use of opioid analgesics, benzodiazepine hypnotics, or antidepressant medications
  • Known allergy to any of the anesthetic agents employed
  • Anticipated difficult airway
  • Increased intracranial pressure
  • Active upper-respiratory-tract infection of the oral, nasal, or pharyngeal regions
  • Severe cardiac insufficiency (functional capacity \< 4 METs)
  • Severe renal failure requiring dialysis prior to surgery
  • Pre-operative oxygen saturation on room air \< 92 %
  • Any condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Supraglottic oxygenation via nasotracheal catheterization Airway Group

    In this group, patients received supraglottic oxygen therapy via nasotracheal intubation.

    Device: wire-reinforced tracheal tube

Interventions

  • Devicewire-reinforced tracheal tube

    Supraglottic oxygen therapy delivered via wire-reinforced nasotracheal tube

06

What researchers measure

Primary outcomes

  1. The incidence of hypoxia(75% ≤ SpO2 < 90% for <60 s)

    Time frame: Periprocedural

Secondary outcomes

  1. The incidence of sub-clinical respiratory depression(90% ≤ SpO2 < 95%)

    Time frame: Periprocedural

  2. The incidence of severe hypoxia(SpO2 < 75% or 75% ≤ SpO2 < 90% for ≥60 s)

    Time frame: Periprocedural

Other outcomes

  1. To observe the incidence of adverse events according to the document from the World SIVA International Sedation Task Force(doi:10.1093/bja/aer407) in patients undergoing bronchoscopy under deep sedation

    Time frame: peri-anesthetic period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2026, 2 months after the start.

Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 2 months is below that.

Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Feb 5, 2026
StartActual
Dec 28, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Mar 30, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07389083
Responsible party
Yueying Zheng (Deputy Director of the Anesthesiology Department, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Feb 5, 2026
Start date
Dec 28, 2025
Primary completion
Feb 28, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Yueying Zheng
Contact
1507128@zju.edu.cn
+8613777408863
Yeke Zhu
Contact
21618018@zju.edu.cn
+8613515815457

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion